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Abstract 
Study objectives: Cardiac involvement and/or macroglossia with soft tissue deposits 
are risk factors for central (CSA) and obstructive sleep apnoea (OSA), and common 
features of systemic AL amyloidosis. Little data exist on the occurrence of sleep 
disordered breathing (SDB) or recurrent nocturnal hypoxia in amyloidosis, which we 
sought to investigate. 
Methods: 72 consecutive patients with systemic amyloidosis (mean age 69 and 
mean BMI 25) were evaluated for occurrence of SDB by overnight continuous pulse 
oximetry and completed Epworth Sleepiness Score (ESS) and STOP BANG 
questionnaires.  Patients included: AL cardiac (AL-C), AL macroglossia (AL-M), AL 
both (AL-CM) and transthyretin (ATTR).   
Results: Mean overnight oxygen saturations were 93% (±SD 2, 95% CI 87-96) with 
abnormal oximetry (4%ODI >5/hour): AC-C 84%, AL-M 57%, AL-CM 62% and ATTR 
- 47%.  NYHA class directly correlated with a higher 4%ODI, NYHA class I versus 3, 
(p=0.01). Two-thirds of patients had STOP-BANG scores greater than 3 and 
abnormally high ESS scores (>10) were seen in up to 30% patients. 
Conclusion: Recurrent nocturnal hypoxaemia, suggestive of sleep disordered 
breathing is frequent in systemic AL amyloidosis.  The higher incidence in cardiac 
amyloidosis raises central CSA and recurrent hypoxia as possible mechanism for 
morbidity/mortality in these cases. A  detailed polysomnography study is planned to 
clarify and investigate these findings further.   
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Highlights: 
1. Sleep disordered breathing is a frequent finding in systemic light chain 
amyloidosis. This was equally prevalent in cardiac and soft tissue 
Amyloidosis patients. 
2. Reduced heart rate variability despite frequent oxygen desaturation was 
associated with increased risk of death in AL Amyloid with Cardiac 
involvement. 
3. Increased awareness of sleep disordered breathing in systemic AL 
Amyloidosis is important and further detailed studies are needed to 
assess its impact on mortality and identify any interventions 
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Background 
Systemic AL amyloidosis is a rare disorder caused by tissue deposition of misfolded 
immunoglobulin light chains leading to progressive organ failure.  Survival of patients 
with amyloidosis depends predominantly on the extent of cardiac involvement.  
Involvement of other organs, particularly soft tissues of the oropharynx, contributes 
to significant symptoms and morbidity.  Although cardiac deaths account for 20-40% 
of all deaths within a few months of diagnosis in AL amyloidosis, the terminal event 
and its triggers remain unclear.  Bradyarrhythmias1 or other arrhythmias may be the 
cause.   
Central sleep apnoea (CSA), characterised by the faulty respiratory drive during 
sleep, is a well-recognised complication of heart failure and can lead to recurrent 
episodes of nocturnal hypoxemia worsening symptomatic heart failure2, causing 
increased morbidity and mortality.  Obstructive sleep apnoea (OSA) is now a well-
recognised cause of acute and chronic adverse cardiovascular effects.  In addition to 
cardiovascular effects, both CSA and OSA cause marked day time fatigue and/or 
sleepiness contributing to morbidity.  Systemic AL amyloidosis is one of the few 
disorders which cause acquired progressive heart failure and can also be associated 
with marked infiltration of the oropharyngeal soft tissues – both potential risk factors 
for CSA or OSA, respectively, or CSA and OSA together in patients with soft tissue 
and cardiac disease.  If SDB occurs in a patient with amyloidosis, the recurrent 
hypoxic episodes could have a profound deleterious effect on the cardiac function 
contributing to morbidity and possibly mortality.   
We report here the results of a study of sleep disordered breathing as evidenced by 
recurrent nocturnal hypoxaemia by overnight continuous pulse oximetry in patients 
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with systemic amyloidosis, showing a high incidence of SDB and raise a question as 
to whether these desaturations may be the trigger for sudden cardiac mortality.  
Methods 
Study Population 
This included all patients with suspected cardiac or macroglossia findings seen at 
the UK National Amyloidosis Centre between July 2013 and June 2014 who 
underwent overnight oximetry for possible sleep disordered breathing, with no 
patient having a prior history of sleep disordered breathing and a previous evaluation 
for OSA  Amyloid deposition was confirmed on a tissue biopsy by the presence 
demonstration of Congo red positivity under cross polarise light and fibril typing was 
done by immunohistochemistry or mass spectrometry.  All patients had a detailed 
assessment for organ involvement as per standard protocol at the National 
Amyloidosis Centre.  Blood tests included a full blood count, renal, liver and bone 
profiles, cardiac biomarkers including N terminal fragment of the prohormone brain 
natriuretic peptide (NT-proBNP) and troponin T.  Other investigations included an 
electrocardiograph (ECG), echocardiography and 123I serum amyloid P component 
(SAP) scintigraphy.  Organ involvement, haematologic and organ responses were 
classified according to the updated international amyloidosis consensus criteria.3  
Written consent for retrospective publication of data was obtained from all patients in 
accordance with the Declaration of Helsinki. 
All patients underwent overnight pulse oximetry using a Minolta 300i pulse oximeter.  
An episode of significant desaturation was defined as a 4% or greater decrease in 
oxygen saturation from the average oxygen saturations in the preceding 120 
seconds.  The oxygen desaturation index (ODI), the hourly average number of 
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desaturation episodes over the whole night, was calculated.  ODI is a standard 
measure used to score oxygen desaturations, but may not always show evidence of  
hypopnoea.4  Heart rate (HR) variability was defined as HR change of >6 beats per 
minute to assess whether patient developed appropriate tachycardia as a normal 
physiological response to desaturation.5  
All patients completed the Epworth Sleepiness Score (ESS) and STOP BANG 
questionnaires for obstructive sleep apnoea (OSA).  The STOPBANG (Snoring, 
Tiredness during the daytime, Observed apnoea, high blood Pressure, Body mass 
index, Age, Neck circumference and Gender) and ESS (Epworth Sleepiness Scale) 
(included as supplementary data) are validated screening tools of OSA with a high 
sensitivity6 but low specificity.  Patients were classified as high risk of OSA if the 
STOP-BANG score was greater than and equal to 3 and low risk if the score was 
less than 3. The ESS (Epworth Sleepiness Scale) questionnaire is based on the 
probability to fall asleep during different situations7 and patients were classified as 
being high risk if the ESS score was greater than or equal to 10.   
Baseline characteristics and clinical investigations are presented as medians with 
minimum and maximum values for continuous variables and percentages with 
proportions for categorical variables.  Statistical significance for comparison between 
groups was analysed with the one way anova variance for continuous variables and 
Turkey post-test analysis using the Graph pad prism version 5 software. Correlation 
statistics were performed using linear scatter plots and Pearson coefficients.  A two-
sided P value of less than 0.05 was considered as statistically significant.  A 
univariate model was used to assess the poor prognostic features of those 
diagnosed with cardiac AL.  Multivariate models are not presented due to instability 
from small patient numbers.  Survival was assessed by the method of Kaplan-Meier 
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analysis and patients with cardiac AL amyloidosis and those with transthyretin 
amyloidosis were analysed separately due to a different disease natural history. 
Results 
Baseline Characteristics 
A total of 72 patients were included in this study. The median age of all patients was 
68.8 years (range 47-83 years).  Eighty percent of the patients had cardiac 
involvement with a median NT-proBNP 2568ng/L (range 136-146203 ng/L).  The 
median 4% ODI 7.9 (range 0.9-59).  Patients were stratified as systemic AL 
amyloidosis with cardiac involvement (AL-C), AL amyloidosis with no cardiac 
involvement but only macroglossia (AL-M), AL amyloidosis with both macroglossia 
and cardiac involvement (AL-CM) and wild type transthyretin amyloidosis (ATTR).  
Table 1 illustrates the baseline presenting characteristics in each group. One patient 
in the AL-M group has an elevated NT-proBNP due to end stage renal impairment. 
 
Overnight Oximetry  
Overnight oximetry tracings were recorded in all 72 patients and shown for the four 
groups (and patients who died) in Table 2. The mean oxygen saturation of all 
patients in the study was 93% (±SD 1.99, range 87-96%).  There was no significant 
difference in the mean oxygen saturations across the groups.  The ATTR group had 
the lowest number of abnormal oximetry tracings.  Figure 1A illustrates a normal 
tracing of overnight oxygen desaturations and pulse in a patient with cardiac 
amyloidosis showing repeated desaturations, with an abnormal tracing of these 
parameters illustrated in Figure 1B.  The 4% ODI was highest in patients with cardiac 
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AL at a median 11 episodes (range 1-48)) compared to patients with macroglossia, 
cardiac and macroglossia and ATTR amyloidosis (6.02 (p=0.94), 6.03 (p=0.17) and 
8.39 (p=0.34) episodes respectively, (Figure 2A).  The absolute number of 4% ODI 
episodes per night were calculated for each group (cardiac AL, AL macroglossia, AL 
cardiac and macroglossia and ATTR) respectively and were: more than 15 per night 
– 32%, 14%, 18% and 29% respectively; and between 10-15 episodes per night in 
20%, 21%, 6% and 12% respectively. Heart rate variability (a HR change of >6 beats 
per minute), a normal physiological response to desaturation, was seen in: cardiac 
AL amyloidosis - 17/25 (68%), patients with macroglossia - 10/14(71%), ATTR - 
15/17(88%), and cardiac and macroglossia patients - 13/16 (81%), and in the 
patients who died - 8/12 (67%), (Figure 2B). The patients who died, as a group, had 
a lower blood pressure, more abnormal oxygen oximetry readings, a high ESS score 
(including proportion with ESS >10), in addition to markers of poorer cardiac function 
like a higher NT-proBNP and lower TAPSE.  
The left ventricular ejection fraction (LVEF) in all groups group (cardiac AL, AL 
macroglossia, AL cardiac and macroglossia and ATTR) were recorded, with a 
median value of 55%, 61%, 56.5% and 41% respectively. There was a significant 
difference between the ATTR group and cardiac AL (p=0.0004) and the ATTR group 
and the macroglossia groups (P<0.0001). There was no significant correlation with 
LVEF and 4%ODI in any amyloid type groups. 
The STOP-BANG and ESS questionnaires were completed by all 72 patients. The 
STOP-BANG score all four groups were high (71%, 69%, 71% and 64%) and would 
suggest a high risk of OSA, (Figure 2C).  An abnormally high ESS score (>10) was 
seen in 28%, 21%, 19%, 24% in patients in the four groups, (Figure 2D).  It was 
higher in those with cardiac AL (28%) and those who died (33%). 
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Relationship between overnight oximetry and cardiac amyloidosis 
In all patients with cardiac AL amyloidosis, increasing NYHA class directly correlated 
with a higher incidence of 4% ODI (NYHA 1-2 n=29, NYHA 3, n=12, NYHA 1 vs. 2 
(p=0.004), NYHA 1 vs 3 (p=0.01); figure 3).  A higher NT-proBNP significantly 
correlated with reduced heart rate variability (correlation coefficient r2 0.185, 
p=0.0002)   There was no correlation of 4% ODI with right ventricle Doppler imaging 
(RVS TDI) (r2=0.02, p=0.4) or tricuspid annular plane systolic excursion (TAPSE) 
(r2=0.02, p=0.4).  There was no correlation between TAPSE and heart rate variability 
(r2=0.030; p = 0.30). 
The median follow up for all cardiac amyloidosis patients was 10 months (range 2-
15), with 12 deaths: 11 with cardiac AL and 1 with ATTR.  The overall survival for the 
cohort stratified by AL-C (including AL-CM), AL-M and ATTR is illustrated in figure 4, 
with the worst prognosis in the cardiac AL group. Higher NYHA class and NT-
proBNP, well recognised markers of poorer prognosis in cardiac amyloidosis, were 
also markers of poorer prognosis in this study.  On univariate analysis of newly 
diagnosed cardiac AL patients (table 3), the factors significantly impacting survival 
included:  TAPSE (HR 0.69, p=0.01) and NT-proBNP (HR 2.79, p=0.04). Small 
patient numbers make a multivariate model unreliable.   
Discussion 
Patients with systemic AL amyloidosis present complex clinical problems due the 
multisystem nature of the disease and complex interaction between tissue deposition 
of the amyloid fibrils and organ dysfunction.  Standard assessment of outcomes and 
symptoms has been focused on tests of organ function and is dominated by 
abnormal cardiac markers.  Sleep disordered breathing is a well-recognised cause of 
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fatigue, day time sleepiness and is associated with increased cardiovascular 
morbidity/mortality.  In this study, using overnight oximetry, we report a high 
incidence of repeated and significant nocturnal hypoxaemia strongly suggestive of 
sleep disordered breathing in patients with systemic amyloidosis.  The extent of 
nocturnal desaturations correlated with the worsening grade of heart failure and 
worse right ventricular function – both markers of poor prognosis suggesting a 
possible role for SDB in worsening organ function in amyloidosis.   
Overnight pulse oximetry is the most commonly used screening method for sleep 
apnoea, with the sensitivity ranging from 31 to 98% and specificity of 41-100%.8-10  It 
gives a continuous recording of oxygen desaturations with a characteristic pattern of 
overnight oxygen desaturations as well as heart rate data.  Clinical prediction models 
are useful with sensitivities between 76-96% and specificities 13-54% and useful in 
excluding a diagnosis,11 but in conjunction with pulse oximetry can confirm the 
presence of sleep apnoea.12 
Our initial hypothesis at the start of the study was that SDB would be more prevalent 
in patients with macroglossia or soft tissue amyloid deposits due to the severe 
anatomical alterations.  The striking finding in our study was presence of significant 
overnight oxygen desaturations in all groups of patients.  Although patients with 
macroglossia/soft tissue amyloidosis had 4% ODIs, these were less frequent than in 
the cardiac AL group, SDB was not seen in all cases AL-M. Collapsibility of the 
upper airway is hallmark of OSA.  Our findings, of less than expected severe 
desaturations in patients with significantly narrow upper airway due to soft tissue 
amyloid deposits raises an interesting question whether the increased stiffness of the 
soft tissue, which is a hallmark of amyloid deposition, actually protects against upper 
airway collapse. 
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Central sleep apnoea (CSA) is a well-recognised complication of systolic heart 
failure, is worse in patients with an ejection fraction of <40% and has been reported 
to be associated with increase in non-sustained ventricular tachycardia as well as 
reduction in heart rate variability.13  The occurrence of repeated severe nocturnal 
oxygen desaturations seen in patients with cardiac amyloidosis raises the possibility  
that CSA also occurs in AL amyloidosis – a finding that will need further investigation 
by polysomnography.  In our study, the oxygen desaturations were greatest in those 
with cardiac AL and 4% ODI correlated with NYHA class and NT-proBNP – 
suggesting a direct correlation with worsening amyloid burden/heart failure with ODI.  
The small numbers of newly diagnosed patients in this study precluded any 
meaningful survival analysis of impact of the number of 4% ODIs. Patients with new 
diagnosis of AL amyloidosis, have the most unstable heart disease, with 30-40% 
patients dying of cardiovascular complications within 6 months.  Although the exact 
cause of death in AL amyloidosis remains unclear, our finding of frequent nocturnal 
hypoxia in such cases raises an important question – does repeated hypoxemia play 
a role by increasing the risk of arrhythmias or worsening myocardial function or both.   
Persistent and profound fatigue is a symptom in AL amyloidosis which has never 
been adequately explained and attributed vaguely to multifactorial organ 
involvement. Recurrent hypoxaemia and sleep disordered breathing may well be a 
substantial contributor to this symptom.   
Restrictive cardiomyopathy in cardiac AL, means that cardiac output can only be 
increased by increase in heart rate. An interesting finding in this study was the lack 
of or markedly reduced heart rate variability in patients with cardiac AL amyloidosis.  
This lack of heart rate response to hypoxia was greater in AL amyloidosis than in the 
patients with ATTR cardiac amyloidosis.  Cardiac autonomic dysfunction is a known 
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phenomenon in AL and ATTR amyloidosis as well as systolic heart failure. 14,15.16-19  
The lack of heart rate variability was most marked in the patients who died. This 
finding suggests that pulse oximetry could help identify patients with  cardiac 
autonomic denervation and open a potential therapeutic avenue for consideration of 
device therapy to counter lack of autonomic drive.  
A recent  randomised study (SERV-HF) in systolic heart failure showed that 
controlling CSA with assisted servo ventilation (ASV) did not improve survival.20  The 
restrictive cardiomyopathy in AL is however very different from systolic heart failure 
requiring different treatment strategies. Reducing recurrent hypoxia with simple 
intervention like oxygen supplementation therefore needs to be studied.  The current 
findings also raise the possibility of using overnight pulse oximetry to provide 
objective data which could potentially be used to monitor disease progression or to 
assess response to treatment.  
We recognise the limitations of this pilot study. It is a small observational cohort 
study and we used overnight pulse oximetry rather than formal polysomnography 
thereby limiting our ability to confirm the cause of the recurrent nocturnal hypoxia 
and clarify type of SDB. We also did not use pulse plethysmography data as the 
main aim was to explore and confirm the presence of oxygen desaturations in 
patients with systemic amyloidosis.  Moreover a significant proportion of patients had 
cardiac dysfunction as well as the possibility of autonomic involvement which would 
make PPG data difficult to interpret without polysomnography. The patient cohort 
was heterogeneous limiting ability to assess impact of desaturations on outcomes.  
We intend to address these issues in future studies 
Conclusions 
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In conclusion, recurrent nocturnal oxygen desaturations, suggestive of sleep 
disordered breathing, are very common in patients with cardiac amyloidosis (both AL 
and ATTR type) as well as in patients with soft tissue amyloid deposits affecting the 
oropharyngeal tract. The extent of nocturnal hypoxia correlated with worsening 
markers of heart failure and worse right ventricular function.  Lack of heart rate 
variability (suggesting cardiac autonomic neuropathy) is a frequent occurrence in 
cardiac AL and particularly in those patients who died – findings which need further 
clarification.  The role of hypoxia caused by SDB in precipitating cardiac arrhythmias 
or causing sudden death in AL needs to be clarified.  Nocturnal hypoxia is a simple 
target for intervention in cardiac AL amyloidosis and could potentially help to reduce 
early mortality in AL which has remained an unmet medical need for over 25 years.   
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Table 1. Patient characteristics 
Type 
Number 
Cardiac AL 
n=25 
Macroglossia 
AL 
n=14 
Cardiac & 
Macroglossia 
AL n=16 
ATTR 
n=17 
Patients Who 
died n=12 
Age (years) 66 (49-80) 71 (47.4-83.8) 65 (39.3-81) 75 (61-83) 69 (59-83) 
Organ Involvement  
Heart 25 (100%) 0 16 (100%) 17 (100%) 12 (100%) 
Kidneys 14 (56%) 4 (29%) 5 (31%) 0 7 (58%) 
Liver 8 (32%) 0 0 0 3 (25%) 
Macroglossia 0 14 (100%) 16 (100%) 0 3 (25%) 
Mayo Disease Stage 
1 4 (16%) 7 (50%) 2 (12%) 2 1 (8%) 
2 9 (36%) 6 (43%) 6 (38%) 5 1 (8%) 
3 12 (48%) 1 (7%) 8 (50%) 10 10 (84%) 
NT-proBNP 
(ng/L) 
5585 (136-
146203) 
186 (34-
11788) 
1314 (136-
13288) 
3703 
(847-12712) 
6619  
(424-146203) 
Troponin T 
(ng/L) 
0.1 (0-0.8) 0.02 (0.01-0.1) 0.07 (0.01-0.15) 0.083 (0.04-
0.63) 
0.09 (0.01-0.8) 
Albumin (g/L) 42 (24-49) 40.5 (30-46) 40.5 (30-52) 46 (43-50) 36 (25-46) 
Alk Phos (IU/L) 81 (37-636) 76 (59-123) 82 (49-135) 109 (69-187) 83 (64-315) 
Creatinine 
(µmol/L) 
105 (58-582) 75 (46-472) 88 (45-385) 126 (70-188) 109 (71-226) 
eGFR 
(mls/min) 
59 (10-100) 73 (10-100) 71 (10-100) 52 (31-100) 60 (26-77) 
GGT (U/L) 49 (12-621) 34 (7-213) 21 (9-153) 114 (42-310) 39.5 (9-621) 
Urinary protein 
(g/24 hours) 
0.2 (0.1-6.8) 0.2 (0.1-4.8)  0.2 (0.1-0.4) 0.9 (0.1-6.8) 
LVEF (%) 55 (43-70) 61 (50-69) 56.5 (38-70) 41 (30-61) 49.5 (28-70) 
RV TDI (cm/s) 0.12 (0.08-0.18) 0.15 (0.09-
0.21) 
0.12 (0.06-0.2) 0.09 (0.05-0.17) 0.11 (0.06-
0.19) 
TAPSE (mm) 15 (6-27) 22 (12-31) 17.5 (7-31) 12 (7-20) 12 (6-22) 
Mean pulse 
(bpm) 
77 (60-108) 68 (55-93) 72 (56-89) 69 (53-80) 80 (61-108) 
Mean systolic 
BP (mmHg) 
109 (91-150) 117 (102-154) 120 (102-166) 123 (106-151) 102 (96-150) 
AL – light chain; BMI – body mass index; ATTR – transthyretin; BP – blood pressure; 4%ODI - hourly 
average number of desaturation episodes defined as a 4% decrease in saturations from the average 
saturations in the preceding 120seconds and lasting for more than 10seconds; NT-proBNP – N 
terminal of the prohormone brain natriuretic peptide; eGFR – estimated glomerular filtration rate; GGT 
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– gamma-glutamyltransferase; LVEF – left ventricular ejection fraction; RV TDI – right ventricle tissue 
Doppler imaging; TAPSE – tricuspid annular pulmonary systolic excursion; cm – centimetres; bpm – 
beats per minute;; pMol/L – picomoles per litre; ng/L – nanograms per litre; g/L – grams per litre; IU/L 
– international units per litre; µmol/L – micromoles per litre; mls/min – millilitres per minute; U/L – units 
per litre; g – grams; cm/s – centimetres per second; mm – millilitres. 
 
 
 
 
 
Table 2. Oximetry data in the different amyloid groups 
Type 
Number 
Cardiac AL 
n=25 
Macroglossia 
AL 
n=14 
Cardiac & 
Macroglossia AL 
n=16 
ATTR 
n=17 
Patients Who 
died n=12 
BMI  25 (18-30) 25.5 (19-45) 25.3 (19-32) 26 (21-37) 23.4 ( 19-26) 
Neck circ (cm) 39 (31-44) 39 (34.3-43) 38 (33-42) 41 (34-45) 40 (34-43) 
ESS and STOP BANG scores 
ESS score 8 (0-15) 6 (2-13) 6 (1-12) 5 (2-17) 8 (0-15) 
ESS>10 7/25 (28%) 3/14 (21%) 3/16 (19%) 4/17 (24%) 4/12 (33%) 
STOP BANG 
score 
3 (1-5) 3 (2-5) 3 (1-6) 4 (1-6) 3 (1-4) 
STOP BANG>3 16/25 (64%) 10/14 (71%) 11/16 (69%) 12/17 (71%) 8/12 (67%) 
Oxygen saturations, ODI and HR variability 
Mean oxygen 
saturations 
93 (88.7-96) 93 (87-96) 94 (91-96) 94 (91-96) 93 (88-96) 
Abnormal 
Oximetry 
21/25 (84%) 11/14 (79%) 10/16 (63%) 9/17 (53%) 9/12 (75%) 
4% ODI 11 (1-48) 6 (3-41) 6 (0.9-52.1) 8 (0.57-59) 6 (3.8-26) 
Heart rate 
change >6bpm 
12 (1.9-113) 13 (4.3-51.5) 20 (2.3-69.7) 24 (0.3-80) 10 (0.3-113) 
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AL – light chain; ATTR – transthyretin based disease; circ – circumference; n – number; BMI – body 
mass index; cm – centimetres; bpm – beats per minute; 4%ODI – hourly average number of 
desaturation episodes defined as a 4% decrease in saturations from the average saturations in the 
preceding 120seconds and lasting for more than 10 seconds; STOP BANG - Snoring, Tiredness 
during the daytime, Observed apnoea, high blood Pressure, Body mass index, Age, Neck 
circumference and Gender; ESS – Epworth Sleepiness Score; mmHg – millimetres of mercury 
 
 
 
 
Table 3. New Cardiac AL  
Variable HR (95% CI) p 
Univariate Analysis 
Neck circumference* 1.37 (0.31-6.13) 0.68 
Body mass index*  0.81 (0.63-1.04) 0.10 
Mean oximetry* 1.03 (0.7-1.52) 0.88 
Abnormal pulse oximetry 0.20 (0.04-1.002) 0.05 
Mean pulse*  1.05 (1.0-1.11) 0.12 
Systolic blood pressure* 0.96 (0.92-1.01) 0.13 
Heart rate variability>6bpm* 1.03 (0.97-1.07) 0.08 
4%ODI* 0.95 (0.87-1.04) 0.28 
TAPSE* 0.69 (0.51-0.92) 0.01 
dFLC >180mg/L 0.14 (0.02-1.18) 0.07 
NT-proBNP* 2.79 (0.54-14.38) 0.04 
bpm – beats per minute; TAPSE – tricuspid annular pulmonary systolic excursion; dFLC – difference 
between involved and uninvolved free light chains; 4%ODI – hourly average number of desaturation 
episodes defined as a 4% decrease in saturations from the average saturations in the preceding 
120seconds and lasting for more than 10seconds; AL – light chain. 
* denotes continuous variables 
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Figure 1A and 1B.  Overnight oximetry tracing of 2 patient with cardiac amyloidosis 
showing oxygen saturations (red tracing) and pulse variability (blue tracing). A 
normal oximetry tracing is illustrated in Figure 1B, with the mean SpO2 of 94.6% and 
3% ODI of 3.6 events per hour. Figure 1C illustrates grossly abnormal oximetry 
findings with the mean SpO2 of 96% and 3% ODI of 46 events per hour.  
Figure 2A and 2B. Relationship of 4%ODI and heart rate change greater than 6bpm 
in different types of amyloid respectively. This illustrates that cardiac AL patients 
experience the highest number of oxygen desaturations and have reduced heart rate 
variability. 
Figure 2C and 2D STOP BANG questionnaire and ESS questionnaires in different 
amyloid groups respectively, showing evident elements of obstructive sleep apnoea 
and central sleep apnoea in these different groups. There is a relative lower risk of 
obstructive sleep apnoea and high risk of central sleep apnoea in cardiac AL 
patients. 
20 
 
Figure 3. Relationship between 4%ODI and NYHA class symptoms in cardiac AL 
patients, showing that increasing NYHA class directly correlated with higher 
incidence of 4% ODI; NYHA 1 vs. 2 (p=0.004), NYHA 1 vs 3 (p=0.01).  
Figure 4.Kaplan Meier curves illustrating the (A) overall survival categorised by the 
type of amyloidosis: including cardiac AL (solid line), soft tissue involvement with 
macroglossia (dashed line) and ATTR (dotted line). 
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